Michael J. Valentino自2011年7月起担任执行董事长，有着30多年的医疗保健行业经验，包括在大型制药公司和风险支持初创企业担任多个重要领导职位。他之前从2009年6月到2010年5月担任Xanodyne Pharmaceuticals, Inc.总裁和首席执行官。Valentino从2003年6月起成功将Adams Respiratory Therapeutics成长为一个完全集成的专业制药公司，年收入超过4.9亿美元，领先OTC品牌，例如Mucinex 和 Delsym。在他的领导之下，Adams于2005年7月完成了公开上市，The Wall Street Journal评论其为2005年度的首位医疗保健IPO；2007年12月公司订立明确协议，它将会被Reckitt Benckiser（家庭清洁、健康和个人护理全球供应商）收购，价格将近为23亿美元。之前，Valentino曾担任Alpharma（一家领先的全球基金制药公司）总裁和首席运营官。加入Alpharma之前，他在Novartis AG担任加入公司之前和客户制药全球主管。他的早期经验包括担任北美Novartis Consumer Healthcare,总裁和首席运营官。Valentino还曾担任Pharmacia & Upjohn’s Consumer Products Division总裁。在他的整个职业生涯期间，Valentino一直活跃在7个大型处方药到OTC转换的前线，包括著名品牌Benadryl, Rogaine Extra Strength, Motrin Jr., Nasalcrom, Lamisil, Voltaren EU 和 Mucinex。他曾担任Consumer Healthcare Products Association董事长。Valentino还担任UrgentRx（一家私人消费品公司）董事长。之前从2009年6月到2010年5月担任Xanodyne Pharmaceuticals, Inc.总裁和首席执行官。Valentino从2003年6月起成功将Adams Respiratory Therapeutics成长为一个完全集成的专业制药公司，年收入超过4.9亿美元，领先OTC品牌，例如Mucinex 和 Delsym。在他的领导之下，Adams于2005年7月完成了公开上市，The Wall Street Journal评论其为2005年度的首位医疗保健IPO；2007年12月公司订立明确协议，它将会被Reckitt Benckiser（家庭清洁、健康和个人护理全球供应商）收购，价格将近为23亿美元。之前，Valentino曾担任Alpharma（一家领先的全球基金制药公司）总裁和首席运营官。加入Alpharma之前，他在Novartis AG担任加入公司之前和客户制药全球主管。他的早期经验包括担任北美Novartis Consumer Healthcare,总裁和首席运营官。Valentino还曾担任Pharmacia & Upjohn’s Consumer Products Division总裁。在他的整个职业生涯期间，Valentino一直活跃在7个大型处方药到OTC转换的前线，包括著名品牌Benadryl, Rogaine Extra Strength, Motrin Jr., Nasalcrom, Lamisil, Voltaren EU 和 Mucinex。他曾担任Consumer Healthcare Products Association董事长。Valentino还担任UrgentRx（一家私人消费品公司）董事长。
Michael J. Valentino has served as Executive Chairman of the Board since July 2011. In June 2003 Mr. Valentino successfully built start-up Adams Respiratory Therapeutics into a fully integrated specialty pharmaceutical company with more than $490 million in annual revenue and leading OTC brands such as Mucinex and Delsym. Under his leadership, Adams completed its initial public offering in July 2005 which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005 and in December 2007 the Company entered into a definitive agreement under which it would be acquired by Reckitt Benckiser, a world leader in household cleaning, health and personal care, for approximately $2.3 billion. Previously, Mr. Valentino was President and Chief Operating Officer at Alpharma, a leading global generic pharmaceutical company. Prior to joining Alpharma, he served as Executive Vice President, Global Head Consumer Pharmaceuticals for Novartis AG. He earlier served as President and Chief Operating Officer of Novartis Consumer Healthcare, North America. Mr. Valentino was also President of Pharmacia & Upjohn’s Consumer Products Division. Throughout his career, Mr. Valentino has been at the forefront of seven major prescription to OTC switches including such well known consumer brands as Benadryl, Rogaine Extra Strength, Motrin Jr., Nasalcrom, Lamisil, Voltaren EU and Mucinex. He has served as Chairman of the Consumer Healthcare Products Association. Michael J. Valentino自2011年7月起担任执行董事长，有着30多年的医疗保健行业经验，包括在大型制药公司和风险支持初创企业担任多个重要领导职位。他之前从2009年6月到2010年5月担任Xanodyne Pharmaceuticals, Inc.总裁和首席执行官。Valentino从2003年6月起成功将Adams Respiratory Therapeutics成长为一个完全集成的专业制药公司，年收入超过4.9亿美元，领先OTC品牌，例如Mucinex 和 Delsym。在他的领导之下，Adams于2005年7月完成了公开上市，The Wall Street Journal评论其为2005年度的首位医疗保健IPO；2007年12月公司订立明确协议，它将会被Reckitt Benckiser（家庭清洁、健康和个人护理全球供应商）收购，价格将近为23亿美元。之前，Valentino曾担任Alpharma（一家领先的全球基金制药公司）总裁和首席运营官。加入Alpharma之前，他在Novartis AG担任加入公司之前和客户制药全球主管。他的早期经验包括担任北美Novartis Consumer Healthcare,总裁和首席运营官。Valentino还曾担任Pharmacia & Upjohn’s Consumer Products Division总裁。在他的整个职业生涯期间，Valentino一直活跃在7个大型处方药到OTC转换的前线，包括著名品牌Benadryl, Rogaine Extra Strength, Motrin Jr., Nasalcrom, Lamisil, Voltaren EU 和 Mucinex。他曾担任Consumer Healthcare Products Association董事长。Valentino还担任UrgentRx（一家私人消费品公司）董事长。之前从2009年6月到2010年5月担任Xanodyne Pharmaceuticals, Inc.总裁和首席执行官。Valentino从2003年6月起成功将Adams Respiratory Therapeutics成长为一个完全集成的专业制药公司，年收入超过4.9亿美元，领先OTC品牌，例如Mucinex 和 Delsym。在他的领导之下，Adams于2005年7月完成了公开上市，The Wall Street Journal评论其为2005年度的首位医疗保健IPO；2007年12月公司订立明确协议，它将会被Reckitt Benckiser（家庭清洁、健康和个人护理全球供应商）收购，价格将近为23亿美元。之前，Valentino曾担任Alpharma（一家领先的全球基金制药公司）总裁和首席运营官。加入Alpharma之前，他在Novartis AG担任加入公司之前和客户制药全球主管。他的早期经验包括担任北美Novartis Consumer Healthcare,总裁和首席运营官。Valentino还曾担任Pharmacia & Upjohn’s Consumer Products Division总裁。在他的整个职业生涯期间，Valentino一直活跃在7个大型处方药到OTC转换的前线，包括著名品牌Benadryl, Rogaine Extra Strength, Motrin Jr., Nasalcrom, Lamisil, Voltaren EU 和 Mucinex。他曾担任Consumer Healthcare Products Association董事长。Valentino还担任UrgentRx（一家私人消费品公司）董事长。 Michael J. Valentino has served as Executive Chairman of the Board since July 2011. In June 2003 Mr. Valentino successfully built start-up Adams Respiratory Therapeutics into a fully integrated specialty pharmaceutical company with more than $490 million in annual revenue and leading OTC brands such as Mucinex and Delsym. Under his leadership, Adams completed its initial public offering in July 2005 which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005 and in December 2007 the Company entered into a definitive agreement under which it would be acquired by Reckitt Benckiser, a world leader in household cleaning, health and personal care, for approximately $2.3 billion. Previously, Mr. Valentino was President and Chief Operating Officer at Alpharma, a leading global generic pharmaceutical company. Prior to joining Alpharma, he served as Executive Vice President, Global Head Consumer Pharmaceuticals for Novartis AG. He earlier served as President and Chief Operating Officer of Novartis Consumer Healthcare, North America. Mr. Valentino was also President of Pharmacia & Upjohn’s Consumer Products Division. Throughout his career, Mr. Valentino has been at the forefront of seven major prescription to OTC switches including such well known consumer brands as Benadryl, Rogaine Extra Strength, Motrin Jr., Nasalcrom, Lamisil, Voltaren EU and Mucinex. He has served as Chairman of the Consumer Healthcare Products Association.
本文链接： http://prestigepharma.immuno-online.com/view-732016.html
